Selective Estrogen Receptor Modulators – an Update (Joint Statement by the German Society for Gynecological Endocrinology and Reproductive Medicine [DGGEF] and the German Professional Association of Gynecologists [BVF])

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology

• Publication date

  2016-06-14

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Endometrial Safety of Ospemifene and the Ability of Transvaginal Ultrasonography to Detect Small Changes in Endometrial Thickness

  2014cited by this paper
• Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene

  2014cited by this paper
• Differential effects of menopausal therapies on the endometrium

  2014cited by this paper
• Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?

  2014cited by this paper
• Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women

  2014cited by this paper
• Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.

  2014cited by this paper
• Evaluation of the Efficacy and Safety of Bazedoxifene/Conjugated Estrogens for Secondary Outcomes Including Vasomotor Symptoms in Postmenopausal Women by Years Since Menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials

  2014cited by this paper
• Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.

  2014cited by this paper
• Ospemifene (Osphena®): A New Treatment for Dyspareunia and Vaginal Atrophy

  2013cited by this paper
• Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.

  2013cited by this paper
• Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study

  2013cited by this paper
• Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

  2013cited by this paper
• Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force

  2013cited by this paper
• Effects of the Selective Estrogen Receptor Modulator Ospemifene on Bone in Rats

  2013cited by this paper
• Profile of Ospemifene in the Breast

  2013cited by this paper
• Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy

  2013cited by this paper
• Hormone therapy for sexual function in perimenopausal and postmenopausal women.

  2013cited by this paper
• Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

  2013cited by this paper
• Ospemifene, vulvovaginal atrophy, and breast cancer.

  2013cited by this paper
• Breast Effects of Bazedoxifene-Conjugated Estrogens: A Randomized Controlled Trial

  2013cited by this paper
• Anti-cancer potential of a novel SERM ormeloxifene.

  2013cited by this paper
• Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells.

  2012cited by this paper
• One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus

  2012cited by this paper
• The Tissue Selective Estrogen Complex: A Novel Approach to the Treatment of Menopausal Symptoms

  2012cited by this paper
• Estrogens plus raloxifene on endometrial safety and menopausal symptoms—semisystematic review

  2012cited by this paper
• The evolution of selective estrogen receptor modulators in osteoporosis therapy

  2012cited by this paper
• Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors

  2012cited by this paper
• Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study

  2012cited by this paper
• Transvaginal Ultrasound for Endometrial Carcinoma Screening - Current Evidence-based Data.

  2012cited by this paper
• The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

  2012cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy

  2011cited by this paper
• Centchroman Regresses Mastalgia: A Randomized Comparison with Danazol

  2011cited by this paper
• The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women

  2011cited by this paper
• Re: Breast cancer risk in relation to the interval between menopause and starting hormone therapy.

  2011cited by this paper
• Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

  2011cited by this paper
• Lasofoxifene for postmenopausal women with osteoporosis.

  2010cited by this paper
• Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis: Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial

  2010cited by this paper
• Fertility drugs and the risk of breast cancer: a meta-analysis and review

  2010cited by this paper
• Clinical pharmacokinetics and interaction of centchroman--a mini review.

  2010cited by this paper
• Effect of Raloxifene on all-cause mortality.

  2010cited by this paper
• Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

  2010cited by this paper
• The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

  2010cited by this paper
• Bayesian integrated modeling of expression data: a case study on RhoG

  2010cited by this paper
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

  2010cited by this paper
• Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

  2010cited by this paper
• A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

  2010cited by this paper
• Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

  2010cited by this paper
• Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

  2009cited by this paper
• Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

  2009cited by this paper
• Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study.

  2009cited by this paper
• Efficacy and safety of ormeloxifene in management of menorrhagia: A pilot study

  2009cited by this paper
• Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer

  2009cited by this paper
• Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Raloxifene and risk for stroke based on the framingham stroke risk score.

  2009cited by this paper
• American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

  2009cited by this paper
• Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors.

  2009cited by this paper
• Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study

  2009cited by this paper
• Pharmacological doses of the natural phyto-SERM DT 56 a ( Femarelle ) have no effect on MCF-7 human breast cancer cell-line

  2009cited by this paper
• Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial

  2008cited by this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cited by this paper
• Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells.

  2008cited by this paper
• The effect of tamoxifen on the genital tract

  2008cited by this paper
• Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis

  2008cited by this paper
• Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

  2008cited by this paper
• Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

  2008cited by this paper
• Effect of raloxifene on the vaginal epithelium of postmenopausal women.

  2008cited by this paper
• Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness.

  2008cited by this paper
• THE EFFECT OF LONG-TERM TAMOXIFEN USAGE ON THE LOWER PART OF FEMALE GENITAL TRACT IN BREAST CANCER SURVIVORS: A REVIEW

  2007cited by this paper
• DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM).

  2007cited by this paper
• Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen.

  2007cited by this paper
• Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

  2007cited by this paper
• The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women.

  2007cited by this paper
• Structure–Activity Relationships for a Family of Benzothiophene Selective Estrogen Receptor Modulators Including Raloxifene and Arzoxifene

  2007cited by this paper
• Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line.

  2007cited by this paper
• A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women

  2007cited by this paper
• Role of Centchroman in Regression of Mastalgia and Fibroadenoma

  2007cited by this paper
• CYP2D6 polymorphisms and the impact on tamoxifen therapy.

  2007cited by this paper
• Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study

  2007cited by this paper
• Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

  2007cited by this paper
• DT56a stimulates gender-specific human cultured bone cells in vitro.

  2006cited by this paper
• Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.

  2006cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Anti-vertebral fracture efficacy of raloxifene: a meta-analysis

  2006cited by this paper
• Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis

  2006cited by this paper
• Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

  2006cited by this paper
• Estrogen receptors and human disease.

  2006cited by this paper
• Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.

  2006cited by this paper
• Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.

  2005cited by this paper
• Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity

  2005cited by this paper
• Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

  2005cited by this paper
• The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

  2005cited by this paper
• Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract.

  2005cited by this paper
• Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice.

  2005cited by this paper
• Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

  2005cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Clomiphene citrate--end of an era? A mini-review.

  2005cited by this paper
• A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.

  2005cited by this paper

• Safety of Ospemifene during Real-Life Use

  2018cites this paper